Novavax falls 12.2% after activist says it will step back

What happened

Novavax (NVAX) fell 12.2% on October 16, 2026, after Shah Capital said it would step back from its activist role at the company, a move Reuters reported as the likely trigger for the heavy trading. The stock closed at $11.26. Trading volume was 1.1 times its 20-day average, and the drop came as the healthcare sector median fell 3.1% and the S&P 500 fell 1.1% on the day.

How big was the move

The session's move was 2.6 times a typical daily move for this stock, a pattern the data classify as "A large, mostly company-specific move" because company news was the likely driver. Novavax fell 11.7% over the last five sessions while the S&P 500 over five sessions fell 1.9%. Compared with its sector, the stock was 9.1 percentage points worse than the sector median on the day. Market sensitivity is shown by a beta of 1.67, indicating the stock tends to move more than the market. In the past five years the stock had 20 sessions with a decline of at least 12.2%; twenty trading days later the median result was a decline of 3.6%, and 8 of 20 were higher.

The technical picture

Technicals showed mixed signals. The share price was 1.0% below its 20-day moving average, yet 12.4% above its 50-day moving average and 23.0% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock had been above the 200-day average for 40 consecutive trading days. The Relative Strength Index (14 days) was 51, inside a neutral range between 30 and 70. The stock remained 15.9% below its 52-week high.

Momentum readings showed gains over recent horizons: change over one month rose 12.6%, over three months rose 42.9%, and over one year rose 26.4%, which placed Novavax 11.6 percentage points ahead of the S&P 500 for the year. Volatility was 75% annualized over 60 days, lower than 67% of its own readings over five years, a sign that recent price swings were relatively restrained compared with some earlier periods.

Fundamentals and valuation

For the four quarters through June 30, 2026, Novavax reported revenue of $413.8 million, a decline of 61.6% from a year earlier and a decline of 52.5% from one quarter earlier. Diluted earnings per share for that period were $-1.52, with earnings per share growth from a year earlier listed as fell 167.3%. Gross margin was 77.9%, down from 88.4% a year earlier, while operating margin was 54.9%, up from 33.0% a year earlier. Free-cash-flow margin was 10.5% and return on invested capital was 36.1%. Share count over one year decreased by 7.1%.

Valuation metrics indicated a free-cash-flow yield of 2.1%. PromtFinance scores ranked the company 47 (Neutral) for Value, 4 (Very weak) for Growth, 59 (Neutral) for Quality, 75 (Positive) for Momentum, 82 (Strong) for Revisions, and 25 (Very weak) for Stability. Those scores point to improving momentum and analyst revisions but continued weakness on growth and stability measures, suggesting investors are betting on earnings and expectation improvement rather than steady revenue expansion.

Earnings and analyst expectations

Novavax last reported on August 6, 2026, with earnings per share of $-0.32 against $-0.38 expected, 15.8% above estimates. The company had posted three consecutive quarters beating estimates, with an average surprise over the last four reports of 48.2% above estimates. The typical two-day reaction after recent reports was rose 5.9%. The next report was scheduled for November 5, 2026.

Analyst coverage consisted of 23 analysts, with a consensus rating of Buy and 74% of analysts giving the stock a Buy or equivalent rating. The consensus price target was $18.00, 59.9% above the closing price.

What to watch

• November 5, 2026: next earnings report date
• Last report on August 6, 2026: earnings per share of $-0.32 against $-0.38 expected, 15.8% above estimates
• Trading volume on October 16, 2026: 1.1 times its 20-day average
• In the past five years the stock had 20 sessions with a decline of at least 12.2%; twenty trading days later the median result was a decline of 3.6%, and 8 of 20 were higher
• Consensus price target: $18.00, 59.9% above the closing price